Menero Med (Tadalafil)

Tadalafil is a PDE5 inhibitor indicated for several urological and cardiovascular conditions.

• Erectile dysfunction: Improves the ability to achieve and maintain an erection sufficient for sexual activity in men with this condition.
• Benign prostatic hyperplasia: Relieves lower urinary tract symptoms associated with prostate enlargement, improving urinary flow.
• Pulmonary arterial hypertension: Enhances exercise capacity by promoting pulmonary vasodilation and reducing vascular resistance.

• Tadalafil selectively inhibits the enzyme phosphodiesterase type 5, preventing the breakdown of cyclic guanosine monophosphate (cGMP) in smooth‑muscle cells. Elevated cGMP levels lead to relaxation of the corpus cavernosum and pulmonary vascular smooth muscle, enhancing blood flow. The drug’s long half‑life allows sustained significant therapeutic activity after a single oral dose, supporting its use in both on‑demand and daily regimens.

Tadalafil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache.
• Flushing: warmth and redness of the face or neck.
• Dyspepsia: indigestion or upset stomach.
• Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects

• Priapism: prolonged erection lasting more than 4 hours, requiring medical attention.
• Sudden vision loss: non‑arteritic anterior ischemic optic neuropathy.
• Sudden hearing loss: abrupt decrease in hearing acuity.

When prescribing tadalafil, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina before use.
• Concomitant nitrates: avoid use with nitrate medications due to risk of severe hypotension.
• Visual disorders: monitor patients with pre‑existing retinal disease for changes.
• Renal or hepatic impairment: adjust therapy based on severity of organ dysfunction.
• Drug interactions: review all concomitant medicines for potential CYP3A4 interactions.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Tadalafil interacts with several drug classes; interactions are classified by their clinical significance.

Major Interactions (Avoid)

• Nitrates (e.g., nitroglycerin): combined use can cause dangerous drops in blood pressure.
• Alpha‑blockers (e.g., doxazosin) in patients with cardiovascular disease: may lead to severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase tadalafil plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of tadalafil.
• Antihypertensive agents: may enhance blood pressure‑lowering effects.
• Other PDE5 inhibitors: concurrent use can increase risk of adverse events.